Evidence map›Paper›PMID 34427293›Full record

ArticleEuropean heart journal. Cardiovascular Imaging2022

A simplified wall-based model for regional innervation/perfusion mismatch assessed by cardiac 123I-mIBG and rest 99mTc-tetrofosmin SPECT to predict arrhythmic events in ischaemic heart failure.

Derk O Verschure, Edwin Poel, Mark I Travin, Milena J Henzlova, Diwakar Jain, Arnold F Jacobson, Hein J Verberne

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in European heart journal. Cardiovascular Imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06965621 (An Open-Label, Exploratory, Phase 2 Scintigraphy Study Evaluating 18F mFBG for Imaging Myocardial Sympathetic Innervation in Subjects With Heart Failure and Implantable Cardioverter-Defibrillators), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06965621 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

An Open-Label, Exploratory, Phase 2 Scintigraphy Study Evaluating 18F mFBG for Imaging Myocardial Sympathetic Innervation in Subjects With Heart Failure and Implantable Cardioverter-Defibrillators

TypeinterventionalSponsorInnervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Ran2025 to 2026Enrolled20ConditionsHeart Failure, Ischemic Cardiomyopathy, ICD PatientsArms18F-metaFluorobenzylguanidine, Rubidium-82
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Establishment of aAnnals of nuclear medicine · 2025
    Article
  2. Article
  3. CardiacPharmaceuticals (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Derk O VerschureDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, theNetherlands.ORCID 0000-0002-3205-5183
Edwin PoelDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, theNetherlands.
Mark I TravinDivision of Nuclear Medicine, Department of Radiology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA.
Milena J HenzlovaDepartment of Cardiology, Mount Sinai Medical Center, 1468 Madison Avenue, New York, NY 10029, USA.
Diwakar JainCardio-Oncology Service, Nuclear Cardiovascular Imaging Laboratory, Department of Cardiology, Westchester Medical Center, New York Medical College, 100 Woods road, Valhalla, NY, 10595, USA.
Arnold F JacobsonDiagram Consulting, 10 Lio Poele Place, Kihei, HI, 96753, USA.
Hein J VerberneDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, theNetherlands.
Amsterdam University Medical Centers · NLAlbert Einstein College of Medicine · USMount Sinai Medical Center · USWestchester Medical Center · USZaans Medisch Centrum · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCardiac 123iodine-meta-iodobenzylguanidine (123I-mIBG) single-photon emission computed tomography (SPECT) imaging provides information on regional myocardial innervation. However, the value of the commonly used 17-segment summed defect score (SDS) as a prognostic marker is uncertain. The present study examined whether a simpler regional scoring approach for evaluation of 123I-mIBG SPECT combined with rest 99mTc-tetrofosmin SPECT myocardial perfusion imaging could improve prediction of arrhythmic events (AEs) in patients with ischaemic heart failure (HF). METHODS AND

resultsFive hundred and two ischaemic HF subjects of the ADMIRE-HF study with complete cardiac 123I-mIBG and rest 99mTc-tetrofosmin SPECT studies were included. Both SPECT image sets were read together by two experienced nuclear imagers and scored by consensus. In addition to standard 17-segment scoring, the readers classified walls (i.e. anterior, lateral, inferior, septum and apex) as normal, matched defect, mismatched (innervation defect > perfusion defect), or reverse mismatched (perfusion defect > innervation defect). Cox proportional hazards ratios (HRs) were used to determine if age, body mass index, functional class, left ventricular ejection fraction (LVEF), B-type natriuretic peptide (BNP), norepinephrine, 123I-mIBG SDS, 99mTc-tetrofosmin SDS, innervation/perfusion mismatch SDS, and our simplified visual innervation/perfusion wall classification were associated with occurrence of AEs (i.e. sudden cardiac death, sustained ventricular tachycardia, resuscitated cardiac arrest, appropriate implantable cardioverter-defibrillator therapy). At 2-year median follow-up, 52 subjects (10.4%) had AEs. Subjects with 1 or 2 mismatched walls were twice as likely to have AEs compared with subjects with either 0 or 3-5 mismatched walls (16.3% vs. 8.3%, P = 0.010). Cox regression analyses showed that patients with a visual mismatch in 1-2 walls had an almost two times higher risk of AEs [HR 2.084 (1.109-3.914), P = 0.001]. None of the other innervation, perfusion and mismatch scores using standard 17 segments were associated with AEs. BNP (ng/L) was the only non-imaging parameter associated with AEs.

conclusionA visual left ventricular wall-level based scoring method identified highest AE risk in ischaemic HF subjects with intermediate levels of innervation/perfusion mismatches. This simple technique for the evaluation of SPECT studies, which are often challenging in HF subjects, seems to be superior to the 17-segment scoring method.

Indexed as

3-IodobenzylguanidineHeart FailureHeartHumansIodine RadioisotopesNatriuretic Peptide, BrainOrganophosphorus CompoundsOrganotechnetium CompoundsPerfusionRadiopharmaceuticalsStroke VolumeTomography, Emission-Computed, Single-PhotonVentricular Function, Left3-IodobenzylguanidineIodine-123Iodine RadioisotopesNatriuretic Peptide, BrainOrganophosphorus CompoundsOrganotechnetium CompoundsRadiopharmaceuticalstechnetium tc-99m tetrofosmin123I-mIBG scintigraphyarrhythmiachronic heart failureinnervation/perfusion mismatch

Identifiers

PMID34427293
PMCPMC9365302
OpenAlexW3195227875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.